Euroclone will sell Precipio's Ice Cold-PCR DNA enrichment products for use with liquid biopsies exclusively in Italy and non-exclusively in the rest of Europe.
The lab, which serves hospitals in India and surrounding countries, will use Precipio's ICE COLD-PCR technology to offer blood-based mutation tests.
More than 90 percent of voting Transgenomic shareholders gave the go-ahead to the deal. Upon completion of the merger, the new firm will take on the Precipio name.
The firm said that its shares will begin trading on the OTCQB exchange starting on Feb. 22.
Under the agreement, Precipio would become a wholly owned subsidiary of Transgenomic, which would then adopt the new name Precipio.
JoyingBio will distribute Transgenomic's multiplexed ICE COLD-PCR kits in China and Biotron Healthcare will do the same in India.
The agreement gives Ventana access to results from a collaboration and licensing agreement that Transgenomic made separately with the University of Melbourne.
The firm's labs services revenues were unchanged, but it saw a slight increase in sales mainly from higher oncology revenue and grants.
Two Boston-based researchers shared methods for detecting circulating nucleic acid biomarkers for potential use in cancer diagnosis and monitoring.
The partners will augment the multiplexing capabilities of ICE COLD-PCR, which was developed at Dana-Farber and is exclusively licensed to Transgenomic.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.